Bisfosfonat' - prodolzhitel'nost' ispol'zovaniya pri osteoporoze, tselesoobraznost' i bezopasnost'


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Today it is possible to tell with confidence that in an arsenal of rheumatologists there is a number of effective medications for fight against osteoporosis, the wide experience of their application are stored. However there are new questions of the purposes of therapy and safe terms of treatment, the ways of change of medications at an inefficiency or emergence of side effects.

Full Text

Restricted Access

About the authors

O. B Ershova

A. V Nazarova

References

  1. Беневоленская Л.И. Руководство по остеопорозу М., 2003. С. 196-216.
  2. Briot K, Tremollieres F1 Thomas T, et al. How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 2007;74(1):24-31.
  3. Bianchi G, Sambrook P. Oral nitrogen-containing bisphosphonates: a systematic review of randomized clinical trials and vertebral fractures. Curr Med Res Opin 2008;24(9):2669-77.
  4. Ott S.M. What is the optimal duration of bisphosphonate therapy? Cleve Clin J Med 2011;78(9):619-30.
  5. Cooper C, Reginster JY1 Cortet B, et al. Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). urr Med Res Opin 2012;28(3):475-91.
  6. Salari P1 Abdollahi M. Long term bisphosphonate use in osteoporotic patients; a step forward, two steps back. J Pharm Pharm Sci 2012; 15(2):305-17.
  7. Boonen S, Ferrari S, Miller PD, et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk - a perspective. J Bone Miner Res. 2012;27(5):963-74.
  8. Charopoulos I, Orme S, Giannoudis PV. Fracture risk associated with chronic use of bisphosphonates: evidence today. Expert Opin Drug Saf 2011;10(1):67-76.
  9. Schneider JP, Hinshaw WB, Su C, Solow P Atypical femur fractures: 81 individual personal histories. J Clin Endocrinol Metab 2012;97(12): 4324-28.
  10. Meier RP1 Perneger TV, Stern R, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012;172(12):930-36.
  11. Diab DL, Watts NB. Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab Clin North Am 2012;41(3):487-506.
  12. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013;126(1):13-20.
  13. Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 2009;7(1):12-7.
  14. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95(4):1555-65.
  15. Soen S. Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture Clin Calcium 2012; 22(6):919-22.
  16. Soong YK, Tsai KS, Huang HY, et al. Risk of за время лечения; снижение маркеров костной резорбции менее чем на 25 %. refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan Osteoporos Int 2013;24(2):511-21.
  17. Yun H, Curtis JR, Saag K. Generic alendronate use among medicare beneficiaries: are part d data complete? Pharmacoepidemiol Drug Saf 2013;22(1):55-63.
  18. Landfeldt E, Ström O. The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis. Bone 2012; 51(4):637-42.
  19. Скрипникова И.А., Рожинская Л.Я. Применение дженериков - способ повьшения приверженности лечению остеопороза // Остеопороз и остеопатии 2010;3:36-40.
  20. Hadji P Ziller V, Gamerdinger D, et al. Quality of life and health status with zolendronic acid and generic alendronate - a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int 2012;23(7):2043-51.
  21. Клинические рекомендации по профилактике и ведению больных с остеопорозом / Под ред. О.М. Лесняк. 2012. 30 с.
  22. Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis.
  23. Osteoporosis Int 2012;23(12):2769-74. doi: 10.1007/s00198-012-2093-8. Epub 2012 Jul 27.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies